Correspondence 0001193125-23-127842 from Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: April 28, 2023 · CIK: 0001501756 · Accession: 0001193125-23-127842
AI Filing Summary & Sentiment
File numbers found in text: 333-271431
Letter
ADVERUM BIOTECHNOGIES, INC.
100 Cardinal Way
Redwood City, California 94063-6548
April 28, 2023
VIA EMAIL AND EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Mail Stop 3720
Washington, D.C. 20549
Attn: Doris Gama
RE: Adverum Biotechnogies, Inc.
Registration Statement on Form S-3
File No. 333-271431
Ladies and Gentlemen:
Adverum Biotechnogies, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on May 2, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth Guernsey of Cooley LLP, counsel to the Registrant, at (415) 693-2091, or in his absence, Brett White at (650) 843-5191.
Very truly yours,
ADVERUM BIOTECHNOGIES, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP ADVERUM BIOTECHNOGIES, INC. 100 Cardinal Way Redwood City, California 94063-6548 April 28, 2023 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3720 Washington, D.C. 20549 Attn: Doris Gama RE: Adverum Biotechnogies, Inc. Registration Statement on Form S-3 File No. 333-271431 Ladies and Gentlemen: Adverum Biotechnogies, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on May 2, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with Kenneth Guernsey of Cooley LLP, counsel to the Registrant, at (415) 693-2091, or in his absence, Brett White at (650) 843-5191. Very truly yours, ADVERUM BIOTECHNOGIES, INC. By: /s/ Linda Rubinstein Name: Linda Rubinstein Title: Chief Financial Officer cc: John Rakow, General Counsel, Adverum Biotechnogies, Inc. Kenneth Guernsey, Cooley LLP Brett White, Cooley LLP